Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.12.23 | After Amryt buyout, Chiesi scores with FDA nod for rare skin disease treatment Filsuvez | 5 | FiercePharma | ||
09.11.23 | IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team | 1 | Alliance News | ||
09.11.23 | Poolbeg Pharma PLC: Former Amryt Pharma Leadership Team join Poolbeg | 218 | ACCESSWIRE | Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg PharmaPoolbeg team boosted by highly experienced executives with track record of successLONDON, UK / ACCESSWIRE / November 9, 2023... ► Artikel lesen | |
09.11.23 | Poolbeg Pharma PLC - Former Amryt Pharma Leadership Team join Poolbeg | 1 | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GILEAD SCIENCES | 60,85 | -0,03 % | Gilead Sciences Aktie: Kurskorrektur voraus? | In den letzten Wochen geriet die Aktie von Gilead Sciences, einem bedeutenden Hersteller von HIV- und Hepatitis-C-Medikamenten, in das Blickfeld der Investoren. Aufgrund verschiedener Faktoren verzeichnete... ► Artikel lesen | |
AURORA CANNABIS | 6,145 | -0,65 % | Nach Aurora, Canopy und Tilray: Diese Cannabis-Aktie ist superheiß | Die Cannabis-Branche hat zuletzt neue Impulse vom Rescheduling in den USA sowie die Freigabe in Deutschland erhalten. Vor diesem Hintergrund ging es für zahlreiche Cannabis-Player teils zweistellig... ► Artikel lesen | |
CANOPY GROWTH | 9,230 | +1,99 % | Canopy Growth Corp (2): Canopy Growth exercises options to acquire Wana, Jetty | ||
TILRAY BRANDS | 1,875 | -1,78 % | Tilray mit EILMELDUNG: Könnte der Kurs JETZT komplett drehen - Dringend reagieren!!! | ||
TEVA | 12,900 | -1,53 % | Novo, Teva, AstraZeneca issued FTC warnings over 'bogus' patents | ||
INNOCAN PHARMA | 0,197 | +2,34 % | Innocan Pharma: Wirksames Medikament für Milliarden Patienten? | ||
CRONOS GROUP | 2,416 | -1,63 % | Why Canopy Growth, Tilray, and Cronos Group Stocks Just Cratered | ||
SYNBIOTIC | 9,100 | -0,44 % | ANLEIHEN-Woche KW17 - 2024: ABO Wind, Groß & Partner, Greencells, ELARIS, FCR Immobilien, Ekosem-Agrar, Werder Bremen, Mutares, paragon, NEON EQUITY, MS Industrie, pferdewetten, Homann Holzw., SynBiotic, Energiekontor, Dt. Rohstoff, LEEF, … | Kalenderwoche 17 am KMU-Anleihemarkt (22.04. bis 26.04.2024) - der erste Green Bond der ABO Wind AG (ISIN: DE000A3829F5) erfährt eine hohe Investoren-Nachfrage in der aktuellen Zeichnungsphase. Das... ► Artikel lesen | |
INCYTE | 50,14 | -0,20 % | Incyte Corporation Q1 Profit Increases, but misses estimates | WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) revealed earnings for its first quarter that increased from last year but missed the Street estimates.The company's bottom line totaled $169.548... ► Artikel lesen | |
ZOETIS | 154,54 | +0,30 % | Zoetis Inc. Q1 Profit Increases, beats estimates | WASHINGTON (dpa-AFX) - Zoetis Inc. (ZTS) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 39,150 | -0,33 % | Ionis Pharmaceuticals, Inc.: Ionis reports first quarter 2024 financial results | WAINUATM launch on track; EU and Canada approval decisions expected this year
Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission
Positive Phase 3 donidalorsen data for HAE;... ► Artikel lesen | |
SNDL | 2,250 | -2,17 % | Lifeway Foods and SNDL among Consumer Staples movers | ||
AMARIN | 0,890 | -1,11 % | Amarin Corporation plc: Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference | ||
NEKTAR THERAPEUTICS | 1,549 | +1,37 % | Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases | Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 69,00 | +1,47 % | Ligand Pharmaceuticals and Agenus enter into royalty financing deal |